Leaflet VIRAFERONPEG 120mcg powder+solution for injection


Indicated for: viral infections; multiple sclerosis; cancer

Route of administration: injectable

Substance: peginterferon alfa 2B (antineoplastic agent)

ATC: L03AB10 (Antineoplastic and immunomodulating agents | Immunostimulants | Interferons)

Precautions:
Fertility warning
Fertility warning

This medicine may affect fertility.

Dose adjustment in hepatic impairment
Dose adjustment in hepatic impairment

Dose adjustment may be needed in liver disease.

Cytotoxic / special handling
Cytotoxic / special handling

Handle with special care.

Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis
Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Severe skin reactions
Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Peginterferon alfa-2b is a medication used for the treatment of chronic hepatitis B and C, as well as certain types of cancer, such as malignant melanoma. It is a pegylated form of interferon that stimulates the immune system to fight viral infections and cancer cells.

The medication is administered as a subcutaneous injection, as directed by your doctor. It is important to follow the administration schedule and monitor liver function and other blood tests during treatment.

Side effects may include fatigue, flu-like symptoms, depression, nausea, or weight loss. In rare cases, severe reactions such as liver function impairment or autoimmune disorders may occur.

Patients should inform their doctor about any other medications being used or pre-existing conditions to ensure the safe use of peginterferon alfa-2b.

General data about VIRAFERONPEG 120mcg

  • Substance: peginterferon alfa 2B
  • Date of last drug list: 01-07-2013
  • Commercial code: W52112003
  • Concentration: 120mcg
  • Pharmaceutical form: powder+solution for injection
  • Quantity: 4
  • Product type: original
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Concentrations available for peginterferon alfa 2B

  • 100mcg
  • 100mcg/0.5ml
  • 120mcg
  • 120mcg/0.5ml
  • 150mcg
  • 150mcg/0.5ml
  • 50mcg
  • 50mcg/0.5ml
  • 80mcg
  • 80mcg/0.5ml